Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Plasma prostacyclin and thromboxane concentrations in 160 normotensive, hypotensive, and preeclamptic patients during pregnancy, delivery, and the post partum period

Plasma prostacyclin and thromboxane concentrations in 160 normotensive, hypotensive, and... Introduction Since the identification of prostacyclin (PGI2) and thromboxane (TxA2) in the seventies [13] there is clear evidence that prostanoids play an important role in the regulation of the circulation. PGI2 is mainly synthesised in the endothelium and in the smooth muscles of the vascular wall and is one of the strongest dilatatory substances in arteries, veins and capillaries. PGI2 causes a significant decrease in blood pressure [13, 23] and is a very potent inhibitor of the aggregation of thrombocytes. Thus, it is an antagonist of thromboxane (TxA2), which is produced in the thrombocytes and has a strong constrictor effect on blood vessels. Besides, PGI2 has an anti-arteriosclerotic effect by direct stimulation of cholesterol catabolism, leading to a release of cholesterol from the vascular wall, which is then removed by HDL proteins [17]. Furthermore, PGI2 is considered to have a cytoprotective function [17]. PGI2 is not stable in aqueous solution at physiological pH. However, 6-keto-prostaglandin Flct, which results from non-enzymatic hydrolysis, serves as a stable marker in plasma, urine and amniotic fluid [21]. TxA2 has a very short halftime too and only its stable metabolite TxB2 is a good marker. The importance of PGI2 and TxA2 for utero-placental http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Journal of Perinatal Medicine de Gruyter

Plasma prostacyclin and thromboxane concentrations in 160 normotensive, hypotensive, and preeclamptic patients during pregnancy, delivery, and the post partum period

Loading next page...
 
/lp/de-gruyter/plasma-prostacyclin-and-thromboxane-concentrations-in-160-normotensive-NMxj0zO0ii

References (20)

Publisher
de Gruyter
Copyright
Copyright © 2009 Walter de Gruyter
ISSN
0300-5577
eISSN
1619-3997
DOI
10.1515/jpme.1993.21.6.481
Publisher site
See Article on Publisher Site

Abstract

Introduction Since the identification of prostacyclin (PGI2) and thromboxane (TxA2) in the seventies [13] there is clear evidence that prostanoids play an important role in the regulation of the circulation. PGI2 is mainly synthesised in the endothelium and in the smooth muscles of the vascular wall and is one of the strongest dilatatory substances in arteries, veins and capillaries. PGI2 causes a significant decrease in blood pressure [13, 23] and is a very potent inhibitor of the aggregation of thrombocytes. Thus, it is an antagonist of thromboxane (TxA2), which is produced in the thrombocytes and has a strong constrictor effect on blood vessels. Besides, PGI2 has an anti-arteriosclerotic effect by direct stimulation of cholesterol catabolism, leading to a release of cholesterol from the vascular wall, which is then removed by HDL proteins [17]. Furthermore, PGI2 is considered to have a cytoprotective function [17]. PGI2 is not stable in aqueous solution at physiological pH. However, 6-keto-prostaglandin Flct, which results from non-enzymatic hydrolysis, serves as a stable marker in plasma, urine and amniotic fluid [21]. TxA2 has a very short halftime too and only its stable metabolite TxB2 is a good marker. The importance of PGI2 and TxA2 for utero-placental

Journal

Journal of Perinatal Medicinede Gruyter

Published: Jan 1, 1993

There are no references for this article.